{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:30:55Z","timestamp":1775197855856,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chronic Lymphocytic Leukemia Foundation","award":["R25CA56452"],"award-info":[{"award-number":["R25CA56452"]}]},{"name":"National Cancer Institute-NCI","award":["R25CA56452"],"award-info":[{"award-number":["R25CA56452"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Proteomic DNA Damage Repair (DDR) expression patterns in Chronic Lymphocytic Leukemia were characterized by quantifying and clustering 24 total and phosphorylated DDR proteins. Overall, three protein expression patterns (C1-C3) were identified and were associated as an independent predictor of distinct patient overall survival outcomes. Patients within clusters C1 and C2 had poorer survival outcomes and responses to fludarabine, cyclophosphamide, and rituxan chemotherapy compared to patients within cluster C3. However, DDR protein expression patterns were not prognostic in more modern therapies with BCL2 inhibitors or a BTK\/PI3K inhibitor. Individually, nine of the DDR proteins were prognostic for predicting overall survival and\/or time to first treatment. When looking for other proteins that may be associated with or influenced by DDR expression patterns, our differential expression analysis found that cell cycle and adhesion proteins were lower in clusters compared to normal CD19 controls. In addition, cluster C3 had a lower expression of MAPK proteins compared to the poor prognostic patient clusters thus implying a potential regulatory connection between adhesion, cell cycle, MAPK, and DDR signaling in CLL. Thus, assessing the proteomic expression of DNA damage proteins in CLL provided novel insights for deciphering influences on patient outcomes and expanded our understanding of the potential complexities and effects of DDR cell signaling.<\/jats:p>","DOI":"10.3390\/ijms24065481","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:04:46Z","timestamp":1678763086000},"page":"5481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"24","author":[{"given":"Ti\u2019ara L.","family":"Griffen","sequence":"first","affiliation":[{"name":"Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-1255","authenticated-orcid":false,"given":"Fieke W.","family":"Hoff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-4810","authenticated-orcid":false,"given":"Yihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Kornblau","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/10428194.2018.1498494","article-title":"Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"60","author":"Popp","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exphem.2019.02.003","article-title":"DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains","volume":"72","author":"Benito","year":"2019","journal-title":"Exp. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.hoc.2013.01.008","article-title":"17p deletion in chronic lymphocytic leukemia: Risk stratification and therapeutic approach","volume":"27","author":"Schnaiter","year":"2013","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3109\/10428194.2013.829919","article-title":"The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia","volume":"55","author":"Stankovic","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10428190601059829","article-title":"17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis","volume":"48","author":"Turgut","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tahir, S.K., Smith, M.L., Hessler, P., Rapp, L.R., Idler, K.B., Park, C.H., Leverson, J.D., and Lam, L.T. (2017). Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3383-5"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/10428194.2011.631638","article-title":"Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia","volume":"53","author":"Seiffert","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fgene.2015.00011","article-title":"DNA damage response and evasion from immunosurveillance in CLL: New options for NK cell-based immunotherapies","volume":"6","author":"Shatnyeva","year":"2015","journal-title":"Front. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1038\/s41467-021-25403-y","article-title":"Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia","volume":"12","author":"Bloehdorn","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3324\/haematol.2018.203430","article-title":"Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells","volume":"104","author":"Boudny","year":"2019","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62091","DOI":"10.18632\/oncotarget.11388","article-title":"Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells","volume":"7","author":"Zemanova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102026","DOI":"10.1016\/j.ctrv.2020.102026","article-title":"ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias","volume":"88","author":"Boudny","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6603853","article-title":"Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells","volume":"97","author":"Pepper","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1093\/nar\/gks818","article-title":"DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy","volume":"40","author":"McNeil","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1476-4598-9-248","article-title":"Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression","volume":"9","author":"Usanova","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_21","first-page":"3223","article-title":"Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs","volume":"30","author":"Kirschner","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111819","DOI":"10.1016\/j.celrep.2022.111819","article-title":"The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response","volume":"41","author":"Schuhwerk","year":"2022","journal-title":"Cell Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/10428194.2017.1370548","article-title":"Regulation of MAPK signaling and implications in chronic lymphocytic leukemia","volume":"59","author":"Shukla","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/onc.2011.426","article-title":"Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance","volume":"31","author":"Li","year":"2012","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2021-151513","article-title":"Proteomic Profiling Based Classification of CLL Provides Prognostication for Modern Therapy and Identifies Novel Therapeutic Targets","volume":"138","author":"Griffen","year":"2021","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:53:55Z","timestamp":1760122435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065481"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065481","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]}}}